Rupatadine Fumarate

富马酸卢帕他定

Report date: 2025/01/09 17:37:00
NME

Base Information

Drug NameRupatadine Fumarate
Drug Alias NameRupatadinum芦帕他定卢帕他定rupatadinerupatadina +[19] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H1 receptor antagonistsPlatelet-activating factor inhibitors
TargetsHistamine H1 receptorPlatelet-activating factor
Therapy Area/IndicationsChronic UrticariaUrticariaPruritus +[11] 
Global Approved IndicationsUrticariaPruritusEczema +[5] 
Approved Indications in ChinaUrticariaRhinitis, Allergic
Original Approved Country/TerritorySpain
Original Approved Date2001/07/04
Country/TerritoryCanadaPortugalGermany +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesUriach
China Registration ClassN/A

Develop Information

Active CompaniesJ. Uriach & CoNoucor Health SATeikoku Pharma Usa Inc +[5] 
Inactive CompaniesAhn-Gook Pharmaceutical Co LtdCharite University, Berlin, GermanyBeijing Jiashi Lianbo Medicine Technology Co Ltd +[5] 
Active IndicationsUrticariaPruritusEczema +[8] 
Inactive IndicationsChronic UrticariaRhinitis, Allergic, SeasonalRhinitis, Allergic, Perennial

Other Information

ATC CodeR06AX28
Related LinksWikipediaDrugBankKEGG